Skip to main content

Table 1 Baseline patient characteristics

From: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

  Mean (SD) Median (range)
Age (years) 74 (5.1) 74 (65–80)
KPS 87.7 (9.7) 90 (70–100)
Hemoglobin (g/dl) 12.1 (1.3) 12.1 (10.0–14.3)
PSA (ng/ml) 665 (1230) 218.3 (9–5754)
Alkaline phosphatase (U/l) 223 (208) 126.5 (51–768)
Duration of androgen deprivation (months) 65.8 (36.3) 60 (8–132)
Secondary hormonal manipulations 2.4 (1.5) 2 (0–5)
Primary Therapy Number  
   Prostatectomy 13  
   Prostatectomy and radiation 7  
   Radiation alone 2  
   Androgen-deprivation therapy alone 7  
Sites of Disease   
   Bone only 14  
   Visceral only 2  
   Both 6  
\